Recombinant human interferon α2b for injection

Pharmacology: Recombinant human interferon α2b has broad-spectrum antiviral, anti-tumor, cell proliferation inhibition and immune function enhancement. Interferon binds to cell surface receptors to induce cells to produce a variety of antiviral proteins, inhibit virus reproduction in cells, and improve immune function, including enhancing the phagocytic function of macrophages, enhancing the cytotoxicity of lymphocytes to target cells and the function of natural killer cells. Toxicology: Acute toxicity test: The product was injected intraperitoneally and intravenously into mice at doses of 1.5×109IU/kg and 1.5×108IU/kg, respectively, which are 105 and 104 times the therapeutic dose for humans. No acute poisoning symptoms occurred, and no animals died. Long-term toxicity test: The product was injected intramuscularly into rats at doses of 1.5×107IU/kg, 1.5×106IU/kg and 1.5×105IU/kg, 5 times a week for 6 months. There were no abnormalities in the general condition, weight and behavior of the rats. The above test was repeated in rabbits, and no toxic reactions were observed during three months. Pathological tissue examination of the rabbits' internal organs revealed no changes caused by the toxicity of this product.

Recombinant human interferon alpha;2b.

This product is a yellowish or white loose body. After dissolving, it becomes a clear liquid with no insoluble matter visible to the naked eye.

It can be used to treat acute and chronic viral hepatitis (type B, type C, etc.), genital warts, hairy cell leukemia, chronic myeloid leukemia, lymphoma, AIDS-related Kaposi's sarcoma, malignant melanoma and other diseases.

This product can be injected intramuscularly, subcutaneously and at the lesion. 1 Chronic hepatitis B: subcutaneous or intramuscular injection, 3 to 6106 IU/day, change to 3 times/week after four weeks of continuous use, and continue for more than 16 weeks; 2 Acute and chronic hepatitis C: subcutaneous or intramuscular injection, 3 to 6106 IU/day, change to 3 times/week after four weeks of continuous use, and continue for more than 16 weeks; 3 Hepatitis D: subcutaneous or intramuscular injection, 4 to 5106 IU/day, change to 3 times/week after four weeks of continuous use, and continue for more than 16 weeks; 4 Herpes zoster: intramuscular injection, 1106 IU/day, for 6 days, and oral acyclic at the same time; 5 Genital warts: can be used alone, intramuscular injection, 1 to 3106 IU/day, for four weeks. It can also be used in combination with laser or electrocautery. It is generally injected at the base of the wart, 1106IU/time; 6 Hairy cell leukemia: 2-8106IU/m2/day, for at least 3 consecutive months; 7 Chronic myeloid leukemia: 3-5106IU/m2/day, intramuscular injection. It can be used in combination with chemotherapy drugs such as hydroxyurea and Ara-c; 8 Multiple myeloma: as induction or maintenance therapy, 3-5106IU/m2, intramuscular injection, 3 times/week, and combined with chemotherapy regimens such as VMCP; 9 Non-Hodgkin's lymphoma: as induction or maintenance therapy, 3-5106IU/m2, intramuscular injection, 3 times/week, and combined with chemotherapy regimens such as CHVP; 10 Malignant melanoma: 6106IU, intramuscular injection, 3 times/week, combined with chemotherapy drugs; 11 Renal cell carcinoma: 6106IU, intramuscular injection, 3 times/week, combined with chemotherapy drugs; 12 Laryngeal papilloma: 3106IU/m2, intramuscular injection or subcutaneous injection, 3 times a week (once every other day); 13 Kaposi's sarcoma: 50106IU/m2/day, for 5 consecutive days, intravenous drip for 30 minutes each time. There should be at least a 9-day interval before the next 5-day treatment period; 14 Basal cell carcinoma: 5106IU, intratumoral injection, 3 times/week, for 3 weeks; 15 Ovarian cancer: 5-8106IU, intramuscular injection, 3 times/week, combined with chemotherapy drugs.

Common symptoms of this product include fever, headache, chills, fatigue, myalgia, and joint pain, which often occur in the first week of medication. Adverse reactions usually disappear 48 hours after injection. In case of serious adverse reactions, the treatment plan must be modified or the medication must be stopped. If an allergic reaction occurs, the medication should be stopped immediately. A small number of patients may also experience abnormal blood counts such as leukopenia and thrombocytopenia, which can return to normal after stopping the medication. Occasionally, adverse reactions such as anorexia, nausea, diarrhea, vomiting, hair loss, high (or low) blood pressure, and nervous system disorders are seen.

1. Those with a history of allergy to recombinant human interferon α2b or any component of the preparation; 2. Those with severe heart disease; 3. Those with severe liver, kidney or bone marrow dysfunction; 4. Those with epilepsy and central nervous system damage; 5. Those with other serious diseases who cannot tolerate this product.

Seal and store.

5 million IU/vial

Anhui Anke Biotechnology (Group) Co., Ltd.

• Founded in:

  2000-09-28

• Address:

  K-1, Customs Road, High-tech Zone, No. 669, Changjiang West Road, Hefei, Anhui Province

• Tax NO.:

  91340100149030777L

• Registered Funds:

  1,672,553,658 yuan

• Website:

  Log in to view

• Email:

  Log in to view